Compare CHE & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHE | PTCT |
|---|---|---|
| Founded | 1970 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.5B |
| IPO Year | 1994 | 2006 |
| Metric | CHE | PTCT |
|---|---|---|
| Price | $368.43 | $66.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $498.00 | $80.94 |
| AVG Volume (30 Days) | 282.3K | ★ 959.7K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ 18.34 | 7.78 |
| Revenue | ★ $2,529,978,000.00 | $264,734,000.00 |
| Revenue This Year | $6.60 | N/A |
| Revenue Next Year | $6.15 | $19.30 |
| P/E Ratio | $20.26 | ★ $8.61 |
| Revenue Growth | 4.06 | ★ 36.19 |
| 52 Week Low | $368.44 | $35.95 |
| 52 Week High | $623.61 | $87.50 |
| Indicator | CHE | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 25.08 | 47.92 |
| Support Level | N/A | $61.43 |
| Resistance Level | $458.07 | $69.29 |
| Average True Range (ATR) | 8.82 | 2.35 |
| MACD | -1.58 | 0.38 |
| Stochastic Oscillator | 6.19 | 50.28 |
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.